If you’re eyeing Ameresco’s stock, you’re definitely not alone, and the past month has been anything but boring. After months of flying under the radar, Ameresco has suddenly caught the market’s attention, with its shares surging nearly 50% in just the last 30 days. That kind of move is hard to ignore. Whether this is a turning point or just a temporary boost is the big question facing investors right now. Look a little further back, and you’ll see a see-saw ride: while Ameresco bounced back...
In early October 2025, Airship AI Holdings announced it was awarded 16 contracts totaling US$11.0 million from the US Department of Justice and Department of Homeland Security to provide AI-driven surveillance solutions for public safety and investigations.
The selection of Airship AI's Outpost AI platform, following successful pilot deployments that replaced prior systems, highlights increasing federal confidence in the company's proprietary threat detection technology.
We'll examine how...
Biomea Fusion, Inc. recently announced positive 52-week results from its Phase II COVALENT-111 study of icovamenib in type 2 diabetes, reporting statistically significant and clinically meaningful reductions in HbA1c, especially for patients with severe insulin-deficient diabetes and those not reaching glycemic targets on GLP-1 therapy.
The favorable safety profile and planned next steps, including additional trials and ongoing studies, highlight the company’s continued progress in...
Ring Energy, Inc. recently reported mixed fiscal second quarter results and announced plans to reduce its debt by approximately US$18 million during the third quarter.
Analysts maintained strong positive sentiment on the company following these announcements, highlighting confidence in Ring Energy's ongoing financial management and operational adjustments.
We'll examine how Ring Energy's renewed debt reduction strategy may alter the company's investment narrative and future outlook.
The end...
Recently, news highlighted that Cable One is facing sluggish subscriber trends and a projected sales decline, pointing to deteriorating business performance in the most recent quarter.
An important insight is that continued operational and financial headwinds, especially from weakening subscriber growth, have amplified investor concerns regarding the company's outlook and risk profile.
We'll examine how these slowing subscriber additions and anticipated revenue declines may reshape Cable...
Thinking about what to do with StoneX Group stock right now? You would not be alone. After an incredible five-year run with shares climbing over 300%, followed by a 72% gain in the last year alone, plenty of investors are wondering if the stock’s recent pullback is an opportunity or a warning. Yes, the price retreated nearly 5% over the past month, and dipped almost 3% in just the last week, but that comes on the heels of a remarkable YTD climb over 46%. For a company that has quietly...
Thinking of what to do with your SL Green Realty shares? You are not alone. This stock is famous for defying expectations, which means there is always lively debate over whether it is a smart buy, a risky hold, or now just a watch-and-wait situation. If you have been tracking the price lately, you will have noticed some pretty surprising ups and downs. After rallying through the past three years and returning a remarkable 93.9% over that stretch, as well as a strong 74.1% in five years, SL...
This week’s picks cover: How AMD’s OpenAI partnership could ignite a re-rating, why IREN Energy is in phase 3 of a 4-phase transformation to a profitable powerhouse, and how PWR Holdings turned F1 dominance into a springboard for aerospace and EV growth
If you have been watching GoodRx Holdings lately, you are probably weighing whether its current price reflects a hidden bargain or just more risk. At $4.39, the stock has certainly traveled a bumpy road. Despite a nice pop of nearly 4% over the last week, and almost 10% across the past month, the longer-term chart remains tough to ignore. Down roughly 37% over the last year and an eye-catching 92% since its five-year high, GoodRx has given investors moments of excitement mixed with plenty of...
If you're considering what to do with your Healthcare Realty Trust shares, or perhaps thinking about making a move, you're not alone. The stock has been making waves, sometimes subtle, sometimes more noticeable. Over just the past week, there was a minimal dip of -0.1%, and the past month has seen a slightly larger decline of -1.8%. Yet, zooming out, things look far sunnier: Healthcare Realty Trust is up 7.7% so far this year and a solid 9.5% over the last twelve months. Of course, anyone who...
If you’ve been tracking SiriusPoint’s stock, you know this isn’t one of those sleepwalking tickers. Whether you’re eyeing that impressive 259.4% gain over the last three years or sizing up this year’s 15.8% return, SiriusPoint has certainly kept things interesting for shareholders. Even with a slight dip over the last month, it’s clear that investors are reassessing the company’s growth prospects and its risk, potentially setting up for the next big move.
Much of the recent momentum seems...
If you have been watching Wolfspeed stock recently, you have likely noticed some eye-catching movement. After a period of relative calm, shares have surged by 18.4% in the last week alone. For anyone weighing an investment decision, that kind of action can signal renewed optimism in the company or a shift in how the market is assessing risk and reward in this situation.
So what is driving all this buzz? Part of it may be broader developments in the semiconductor industry, where Wolfspeed is a...
If you have been eyeing Floor & Decor Holdings or wondering whether it is time to make a move, you are not alone. The stock is down 4.7% in the last week and a steep 18.0% over the past month, reflecting a tough period for specialty retailers as broader macro concerns and sector jitters have weighed on investor confidence. Year-to-date, shares have slipped by 26.5%, and over the past year, the decline is even sharper at 36.0%. Looking at a five-year view, the stock is actually in negative...
Skye Bioscience (SKYE) has scheduled a special call to present topline data from its Phase 2a clinical trial of Nimacimab, focusing on both monotherapy and combination treatment. Updates like these frequently shape investor sentiment around development-stage biotech stocks.
See our latest analysis for Skye Bioscience.
Skye Bioscience’s latest topline clinical update arrives after a period of muted share price action. Its stock closed at $1.90 and has shown minimal momentum over recent months...
If you are looking for the next move on Soho House & Co stock, you have probably noticed its eye-catching trajectory. This is not a slow and steady story, but one with dramatic swings and the kind of big numbers that spark conversation. Just over the past year, Soho House & Co’s shares have surged 69.1%. If you stretch that lens out to three years, we are talking 114.5% growth, which is well beyond what most lifestyle or hospitality names can boast. Even in recent months, the stock has kept...
